Eosinophilic Esophagitis
Conditions
Brief summary
This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with respect to their medical history, socio-demographic and disease characteristics, comorbidities (including type 2 inflammatory and atopic conditions), concomitant therapies and prior EoE treatments. Furthermore, this NIS aims to describe the long-term effectiveness of dupilumab for the treatment of EoE as assessed by the treating physician and reported by the patient, and its effect on health-related quality of life (HRQoL) during an individual observational period of two years. In addition, data on real-world use patterns and long-term safety data of dupilumab treatment for EoE will be collected.
Detailed description
The study duration for each participant is planned to be 2 years. Total study duration is approximately 4 years.
Interventions
DRUGDupilumab
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Sponsors
Sanofi
Regeneron Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients diagnosed with EoE who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy * Patients for whom the treating physician has decided to initiate new treatment with dupilumab for EoE according to EU-SmPC independently from entry in study or for whom treatment with dupilumab for EoE according to EU-SmPC has been started within the last 7 days. The decision to initiate dupilumab treatment is made by the treating physician and the patient according to the patients' medical need and to the standard of best medical practice. This decision is made independently and before inclusion in this NIS. * ≥ 12 years of age at baseline visit * ≥ 40 kg bodyweight * Voluntary study participation and signed written informed consent by patient and parent(s)/guardian(s), if applicable
Exclusion criteria
* Patients who have a contraindication to dupilumab according to the current EU-SmPC. * Patients who have been treated with dupilumab for more than 7 days * Any acute or chronic condition that, in the treating physician's opinion, would limit the patients' ability to complete questionnaires or to participate in this study or impact the interpretation of the results. * Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study (parallel inclusion in another Sanofi-independent registry might be possible if the patient gives consent) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Descriptive statistical analysis of medical history characteristics | At baseline |
| Descriptive statistical analysis of socio-demographic characteristics | At baseline |
| Descriptive statistical analysis of disease characteristics | At baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolut change from baseline in endoscopic reference score (EREFS) | After 3, 6 (optional), 12 and 24 months of dupilumab treatment | Absolut change from baseline in EREFS (including inflammatory and fibrostenotic subscore) |
| Proportion of patients with eosinophils per high power field (EOS/hpf) < 15 in esophageal biopsies | After 3, 6 (optional), 12 and 24 months of dupilumab treatment | — |
| Change in clinical symptoms from baseline | From baseline until 1, 3, 6, 9, 12, 18 and 24 months of dupilumab treatment | Change in clinical symptoms (as assessed in clinical practice) from baseline |
| Behavioral changes regarding food intake from baseline | From baseline until 1, 3, 6, 9, 12, 18 and 24 months of dupilumab treatment | Behavioral changes regarding food intake (as reported by the patient) |
| Absolute change from baseline in Dysphagia Numerical Rating Scale (NRS) | After 1, 3, 6, 9, 12, 18 and 24 months of dupilumab treatment | Scale from 0 (no trouble to swallow) - 10 (maximum trouble to swallow) |
| Absolute change from baseline in Hospital Anxiety and Depression Scale (HADS) | After 1, 3, 6, 9, 12, 18 and 24 months of dupilumab treatment | — |
| Absolute change from baseline Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) | After 1, 3, 6, 9, 12, 18 and 24 months of dupilumab treatment | — |
| Absolute change from baseline Pediatric Quality of Life Inventory (PEDS-QL) | After 1, 3, 6, 9, 12, 18 and 24 months of dupilumab treatment | — |
| Number of hospitalizations due to EoE | During the last 12 months before baseline and after 12 and 24 months of dupilumab treatment | — |
| Number of sick leave days at work due to EoE | During the last 12 months before baseline and after 12 and 24 months of dupilumab treatment | — |
| Reason(s) for initiation of dupilumab treatment | At baseline | — |
| Descriptive statistical analysis of details on dupilumab treatment | Throughout the study, for approximately 24 months after dupilumab treatment | Descriptive analysis: form of administration, location of administration |
| Analysis of treatment emergent adverse events (TEAEs) | Throughout the study, for approximately 24 months after initiation of dupilumab treatment | Quantity of treatment emergent adverse events, quantity of TEAE that lead to ending of therapy, collection of type of TEAE |
Countries
Germany
Contacts
CONTACTTrial Transparency email recommended (Toll free for US & Canada)
STUDY_DIRECTORClinical Sciences & Operations
Sanofi
Outcome results
None listed